Loading…
Kairos Pharma, Ltd. is projected to decline to $0.2749 by 2027, a -11% move from its current price of $0.31. KAPA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.2961 | $0.3102 | $0.3249 | +0.06% |
| Aug 6 | $0.2907 | $0.3104 | $0.3314 | +0.12% |
| Aug 7 | $0.2866 | $0.3106 | $0.3366 | +0.19% |
| Aug 8 | $0.2832 | $0.3108 | $0.341 | +0.25% |
| Aug 9 | $0.2803 | $0.311 | $0.3449 | +0.31% |
| Aug 10 | $0.2777 | $0.3112 | $0.3486 | +0.37% |
| Aug 11 | $0.2754 | $0.3114 | $0.352 | +0.44% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.2754 | $0.3114 | $0.352 | +0.44% |
| Week 2 | $0.2629 | $0.3127 | $0.372 | +0.87% |
| Week 3 | $0.2539 | $0.3141 | $0.3885 | +1.31% |
| Week 4 | $0.2468 | $0.3154 | $0.4032 | +1.75% |
| Week 5 | $0.2408 | $0.3168 | $0.4168 | +2.20% |
| Week 6 | $0.2356 | $0.3182 | $0.4298 | +2.64% |
| Week 7 | $0.231 | $0.3196 | $0.4422 | +3.09% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company that develops immunotherapy and cell therapies for cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
ENV 105 is an antibody therapeutic in Phase 2 for prostate cancer patients resistant to androgen-targeted therapy, and in Phase 1 for non-small cell lung cancer. In addition, the company’s preclinical programs include KROS 201, which activates T cells using dendritic cells for glioblastoma, and KROS 101, KROS 102, KROS 301, KROS 401, as well as ENV 205 and ENV-105 (carotuximab). Kairos Pharma, Ltd.
was formerly NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.
Kairos Pharma, Ltd. trades under the symbol KAPA in the Healthcare space. The current price is $0.3098, and the company has a market capitalization of $6.63M with a rank of 5023.
A major floor 37.2% below — a decisive break under it would weaken the trend.
The nearest floor, 8.1% below — buyers have tended to step in here.
The nearest ceiling, 39.0% above — a clean break opens room to run.
A major ceiling 121.0% above — clearing it would confirm fresh momentum.
Key KAPA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KAPA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.3046 | Buy | $0.3043 | Buy |
| MA 10 | $0.3099 | Buy | $0.3107 | Sell |
| MA 20 | $0.3288 | Sell | $0.3302 | Sell |
| MA 50 | $0.401 | Sell | $0.392 | Sell |
| MA 100 | $0.4909 | Sell | $0.4797 | Sell |
| MA 200 | $0.6463 | Sell | $0.6327 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.19 | Neutral |
| Stoch RSI (14) | 67.87 | Neutral |
| CCI (20) | -61.34 | Neutral |
| Williams %R (14) | -71.23 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -3.77 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 28.77 | Neutral |
| TRIX (15) | -1.18 | Sell |
| Awesome (5,34) | -0.06 | Sell |
| Ultimate (7,14,28) | 43.36 | Neutral |
| Momentum (10) | -0.00 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 0.30 | Buy |
| ADX (14) | 26.42 | Sell |
| ATR (14) | 0.02 | Info |
The stock’s near-term technical picture is NUETRAL on the 30-day horizon. The RSI14 sits at 40, indicating a neutral momentum. The price is below both the 50-day and 200-day simple moving averages, with SMA50 at $0.4154 and SMA200 at $0.6652. Traders should watch key levels of support at $0.285 and resistance at $0.457.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.285 | $0.31 | $0.413 | 0% | Neutral | |
| $0.2054 | $0.2749 | $0.3961 | -11% | Neutral | |
| $0.2027 | $0.2857 | $0.4363 | -8% | Neutral | |
| $0.1725 | $0.254 | $0.4055 | -18% | Bearish | |
| $0.1885 | $0.2887 | $0.4783 | -7% | Neutral | |
| $0.2322 | $0.3689 | $0.6307 | +19% | Neutral | |
| $0.2181 | $0.3586 | $0.6306 | +16% | Neutral | |
| $0.2361 | $0.4013 | $0.7237 | +29% | Bullish | |
| $0.2221 | $0.3897 | $0.7192 | +26% | Bullish | |
| $0.1715 | $0.3103 | $0.585 | 0% | Neutral | |
| $0.243 | $0.5091 | $1.05 | +64% | Bullish | |
| $0.3158 | $0.7018 | $1.61 | +126% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.285 | $0.31 | $0.3705 | +0.00% |
| September 2026 | $0.2543 | $0.3069 | $0.3848 | -1.02% |
| October 2026 | $0.2687 | $0.3281 | $0.4188 | +6.91% |
| November 2026 | $0.2669 | $0.3291 | $0.4262 | +0.33% |
| December 2026 | $0.2531 | $0.3149 | $0.413 | -4.32% |
Click any year to see its month-by-month KAPA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Kairos Pharma, Ltd.'s 2026 outlook centres on $0.31, within a $0.285 to $0.413 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, KAPA could reach as high as $0.3961, with a base case around $0.2749 and support toward $0.2054 — roughly -11% from $0.31. A consolidation phase looks the most probable path here.
Expect KAPA to range from $0.2027 to $0.4363 through 2028. The $0.2857 average target implies a -8% move from current prices. That is up +4% on the projected 2027 average. Price action looks broadly range-bound.
The KAPA price prediction for 2029 points to an average of $0.254 (low $0.1725, high $0.4055) — a potential decline of -18% on today's $0.31. Expect choppier, lower action through this leg of the cycle.
In 2030, KAPA is projected to trade between $0.1885 and $0.4783, averaging $0.2887 — a potential decline of -7% from today's $0.31. That is up +14% on the projected 2029 average. Price action looks broadly range-bound.
Kairos Pharma, Ltd.'s 2031 outlook centres on $0.3689, within a $0.2322 to $0.6307 range. That is up +28% on the projected 2030 average. That marks a +19% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, KAPA could reach as high as $0.6306, with a base case around $0.3586 and support toward $0.2181 — roughly +16% from $0.31. Price action looks broadly range-bound.
Expect KAPA to range from $0.2361 to $0.7237 through 2033. The $0.4013 average target implies a +29% move from current prices. That is up +12% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The KAPA price prediction for 2034 points to an average of $0.3897 (low $0.2221, high $0.7192) — a potential gain of +26% on today's $0.31. Momentum favours further upside here.
In 2035, KAPA is projected to trade between $0.1715 and $0.585, averaging $0.3103 — a potential gain of 0% from today's $0.31. That is -20% versus the projected 2034 average. A consolidation phase looks the most probable path here.
Kairos Pharma, Ltd.'s 2040 outlook centres on $0.5091, within a $0.243 to $1.05 range. That is up +64% on the projected 2035 average. That marks a +64% change versus current levels. Momentum favours further upside here.
By 2050, KAPA could reach as high as $1.61, with a base case around $0.7018 and support toward $0.3158 — roughly +126% from $0.31. Buyers look set to stay in control over this stretch.
Investing $1,000 in KAPA today (≈ 3,225.806452 KAPA) could be worth
$2,263.97
+$1,263.97 (+126%) by 2050 · US Dollar
Based on the average projected KAPA price of $0.7 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KAPAwould be worth at today's price.
$1,000 invested in KAPA on Jul 31, 2025 (≈ 1,111.111141 KAPA) would be worth
$344.44
-$655.56 (-65.6%) today · 0.34× · US Dollar
Based on a KAPA entry price of $0.9 vs. today's $0.31.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.285 | $1,087.72 | +8.8% |
| 1 month ago | $0.368 | $842.39 | -15.8% |
| 3 months ago | $0.567 | $546.74 | -45.3% |
| 6 months ago | $0.668 | $464.07 | -53.6% |
| 1 year ago | $0.9 | $344.44 | -65.6% |
| All time (1.9y) ago | $2.6 | $119.23 | -88.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KAPA forecast.
Our base-case forecast reaches $0.62 around 2050.
Implied market cap at $0.62: $13.27M
The year-by-year forecast shows a mixed but increasingly constructive path into the longer term. In 2026, the avg price is $0.3098 with a min of $0.285 and a max of $0.4184, and ROI is 0% (neutral). The trajectory weakens into 2027 and 2028, with 2027 avg $0.2725 and ROI −12.1%, and 2028 avg $0.278 with ROI −10.3%.
2029 remains bearish with avg $0.2469 and ROI −20.3%. In 2030, the avg is $0.2856 with ROI −7.8%. The path improves in 2031 (avg $0.3668, ROI 18.4%), 2032 (avg $0.3593, ROI 16%), 2033 (avg $0.4069, ROI 31.3%), and 2034 (avg $0.3831, ROI 23.7%), with 2035 showing a slight pullback (avg $0.2968, ROI −4.2%).
The forecast turns notably bullish in 2040 (avg $0.5033, ROI 62.5%) and remains strong into 2050 (avg $0.6828, ROI 120.4%). These are estimates, not guarantees, and outcomes depend on market conditions and company developments.
Tap a question to reveal the answer.
The forecast shows a 2030 average price of $0.2856, with a min of $0.179 and a max of $0.4901, and an estimated ROI of −7.8%.
The outlook is mixed: near term shows weaker momentum with 2027–2029 declines, but the longer term features notable upside in 2040 (ROI 62.5%) and 2050 (ROI 120.4%). Specific years show varying returns, including 2026 with ROI 0% and 2031–2034 with positive growth.
The 2030 forecast maximum is $0.4901, which is below $0.50.
The current price is $0.3098 and the market cap is $6.63M.
For 2040, the avg price is $0.5033 with ROI 62.5%. For 2050, the avg price is $0.6828 with ROI 120.4%.
Kairos Pharma, Ltd. Community Discussion
0Share your Kairos Pharma, Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.